The anti-angiogenic activity of IL-12 is increased in iNOS-/-mice and involves NK cells

Journal of Molecular Medicine

Volumn 88, Issue 8, 2010, Pages 775-784

  Bielawska Pohl, Aleksandra ^a,b   Blesson, Séverine ^a   Benlalam, Houssem ^a   Trenado, Aurélie ^a   Opolon, Paule ^a   Bawa, Olivia ^a   Rouffiac, Valérie ^a   Dus, Danuta ^c   Kieda, Claudine ^b   Chouaib, Salem ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ D'ORLÉANS   (France)

^c INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

IL 12; INOS; NK; NK cell; NO; Tumor vessels

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; VASCULOTROPIN; NITRIC OXIDE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; LYMPHOCYTIC INFILTRATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN SYNTHESIS; SPLEEN CELL; TUMOR VASCULARIZATION; ANIMAL; C57BL MOUSE; EXPERIMENTAL MELANOMA; GENE INACTIVATION; GENETICS; IMMUNOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ANIMALS; ENDOTHELIAL CELLS; GENE KNOCKOUT TECHNIQUES; INTERLEUKIN-12; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956483700     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-010-0620-7     Document Type: Article

References (40)

1. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G (1989) Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170:827-845
2. Popovic D, El-Shami KM, Vadai E, Feldman M, Tzehoval E, Eisenbach L (1998) Antimetastatic vaccination against Lewis lung carcinoma with autologous tumor cells modified to express murine interleukin 12. Clin Exp Metastasis 16:623-632
3. Kirou KA, Vakkalanka RK, Butler MJ, Crow MK (2000) Induction of Fas ligand-mediated apoptosis by interferon-alpha. Clin Immunol 95:218-226
4. Koblish HK, Hunter CA, Wysocka M, Trinchieri G, Lee WM (1998) Immune suppression by recombinant interleukin (rIL)-12 involves interferon gamma induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect. J Exp Med 188:1603-1610
5. Thomsen LL, Miles DW (1998) Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev 17:107-118
6. Cianchi F, Cortesini C, Fantappie O, Messerini L, Schiavone N, Vannacci A, Nistri S, Sardi I, Baroni G, Marzocca C, Perna F, Mazzanti R, Bechi P, Masini E (2003) Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis. Am J Pathol 162:793-801
7. Salvucci O, Kolb JP, Dugas B, Dugas N, Chouaib S (1998) The induction of nitric oxide by interleukin-12 and tumor necrosis factor-alpha in human natural killer cells: relationship with the regulation of lytic activity. Blood 92:2093-2102
8. Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, Kuppen PJ (2003) NK cells and the tumour microenvironment: implications for NK-cell function and antitumour activity. Trends Immunol 24:603-609
9. Kwiatkowski B, Artrip JH, Michler RE, Itescu S (1997) Human NK cells demonstrate increased adherence and lysis of porcine endothelium following activation with IL-2. Ann Transplant 2:21-25
10. Bielawska-Pohl A, Crola C, Caignard A, Gaudin C, Dus D, Kieda C, Chouaib S (2005) Human NK cells lyse organ-specific endothelial cells: analysis of adhesion and cytotoxic mechanisms. J Immunol 174:5573-5582
11. Kirk AD, Heinle JS, Mault JR, Sanfilippo F (1993) Ex vivo characterization of human anti-porcine hyperacute cardiac rejection. Transplantation 56:785-793
12. Horvath-Arcidiacono JA, Tsuyuki S, Mostowski H, Bloom ET (2003) Human natural killer cell activity against porcine targets: modulation by control of the oxidation-reduction environment and role of adhesion molecule interactions. Cell Immunol 222:35-44
13. Kieda C (2003) How endothelial cell organo-specificity mediates circulating cell homing. Arch Immunol Ther Exp (Warsz) 51:81-89
14. Strasly M, Cavallo F, Geuna M, Mitola S, Colombo MP, Forni G, Bussolino F (2001) IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell crosstalk. J Immunol 166:3890-3899
15. Chen WS, Kitson RP, Goldfarb RH (2002) Modulation of human NK cell lines by vascular endothelial growth factor and receptor VEGFR-1 (FLT-1). In vivo 16:439-445
16. Huang X, Orucevic A, Li M, Gorelik E (2000) Nitric oxide (NO), methylation and TIMP-1 expression in BL6 melanoma cells transfected with MHC class I genes. Clin Exp Metastasis 18:329-335
17. Zhang XM, Xu Q (2001) Metastatic melanoma cells escape from immunosurveillance through the novel mechanism of releasing nitric oxide to induce dysfunction of immunocytes. Melanoma Res 11:559-567
18. Kieda C, Paprocka M, Krawczenko A, Zalecki P, Dupuis P, Monsigny M, Radzikowski C, Dus D (2002) New human microvascular endothelial cell lines with specific adhesion molecules phenotypes. Endothelium 9:247-261
19. Bizouarne N, Denis V, Legrand A, Monsigny M, Kieda C (1993) A SV-40 immortalized murine endothelial cell line from peripheral lymph node high endothelium expresses a new alpha-L-fucose binding protein. Biol Cell 79:209-218
20. Asselin-Paturel C, Lassau N, Guinebretiere JM, Zhang J, Gay F, Bex F, Hallez S, Leclere J, Peronneau P, Mami-Chouaib F, Chouaib S (1999) Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Ther 6:606-615
21. Waldow T, Witt W, Weber E, Matschke K (2006) Nitric oxide donor-induced persistent inhibition of cell adhesion protein expression and NFkappaB activation in endothelial cells. Nitric Oxide 15:103-113
22. Cobbs CS, Brenman JE, Aldape KD, Bredt DS, Israel MA (1995) Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 55:727-730
23. Fitzpatrick B, Mehibel M, Cowen RL, Stratford IJ (2008) iNOS as a therapeutic target for treatment of human tumors. Nitric Oxide 19:217-224. doi:S1089-8603 (08) 00081-5
24. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S (1995) Nitric oxide synthase activity in human breast cancer. Br J Cancer 72:41-44
25. Coulet F, Nadaud S, Agrapart M, Soubrier F (2003) Identification of hypoxia-response element in the human endothelial nitric-oxide synthase gene promoter. J Biol Chem 278:46230-46240
26. Presley T, Vedam K, Velayutham M, Zweier JL, Ilangovan G (2008) Activation of Hsp90-eNOS and increased NO generation attenuate respiration of hypoxia-treated endothelial cells. Am J Physiol Cell Physiol 295: C1281-C1291
27. Ambs S, Merriam WG, Ogunfusika MO, Bennett WP, Ishibe N, Hussain SP, Tzeng EE, Geller DA, Billiar TR, Harris CC (1998) p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med 4:1371-1376 (Pubitemid 28553458)
28. Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K, Emson PC, Moncada S (1995) Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 92:4392-4396
29. Jones MK, Tsugawa K, Tarnawski AS, Baatar D (2004) Dual actions of nitric oxide on angiogenesis: possible roles of PKC, ERK, and AP-1. Biochem Biophys Res Commun 318:520-528
30. Lala PK, Orucevic A (1998) Role of nitric oxide in tumor progression: lessons from experimental tumors. Cancer Metastasis Rev 17:91-106
31. Medot-Pirenne M, Heilman MJ, Saxena M, McDermott PE, Mills CD (1999) Augmentation of an antitumor CTL response in vivo by inhibition of suppressor macrophage nitric oxide. J Immunol 163:5877-5882
32. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, Shin WS, Liao JK (1995) Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 96:60-68
33. Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM (1996) Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci USA 93:9114-9119
34. Butcher EC, Williams M, Youngman K, Rott L, Briskin M (1999) Lymphocyte trafficking and regional immunity. Adv Immunol 72:209-253
35. Yoneda O, Imai T, Goda S, Inoue H, Yamauchi A, Okazaki T, Imai H, Yoshie O, Bloom ET, Domae N, Umehara H (2000) Fractalkine-mediated endothelial cell injury by NK cells. J Immunol 164:4055-4062
36. Mulligan JK, Day TA, Gillespie MB, Rosenzweig SA, Young MR (2009) Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions. Hum Immunol 70:375-382
37. Mulligan JK, Young MR (2009) Tumors induce the formation of suppressor endothelial cells in vivo. Cancer Immunol Immunother 59 (2):267-277
38. Manna PP, Duffy B, Olack B, Lowell J, Mohanakumar T (2001) Activation of human dendritic cells by porcine aortic endothelial cells: transactivation of naive T cells through costimulation and cytokine generation. Transplantation 72:1563-1571
39. Benlalam H, Jalil A, Hasmim M, Pang B, Tamouza R, Mitterrand M, Godet Y, Lamerant N, Robert C, Avril MF, Neefjes J, Tursz T, Mami-Chouaib F, Kieda C, Chouaib S (2009) Gap junction communication between autologous endothelial and tumor cells induce cross-recognition and elimination by specific CTL. J Immunol 182:2654-2664
40. Banich JC, Kolesiak K, Young MR (2003) Chemoattraction of CD34+ progenitor cells and dendritic cells to the site of tumor excision as the first step of an immunotherapeutic approach to target residual tumor cells. J Immunother 26:31-40